Patent intelligence · US
US 7196184
Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene
Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene
Patent details — US 7196184
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 27, 2007
- Expiration
- Mar 22, 2027
- Applicant
- Alnylam Europe AG
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P35/00
Quick answer
US 7196184 (Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene) is held by Alnylam Europe AG. Status: granted. Granted Mar 27, 2007. Expires Mar 22, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alnylam Europe AG
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P35/00
More from Alnylam Europe AG
Related pharmaceutical patents in our USPTO index.
-
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12397013
Extrahepatic delivery
granted -
US 12385043
Modified double-stranded RNA agents
granted -
US 12385044
Modified double-stranded RNA agents
granted -
US 12378553
Modified double-stranded RNA agents
granted -
US 12364762
Biodegradable lipids for the delivery of active agents
granted -
US 12350338
Biodegradable lipids for the delivery of active agents
granted
Frequently asked questions
What is US patent 7196184?
US 7196184 (Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene) is held by Alnylam Europe AG. Status: granted. Granted Mar 27, 2007. Expires Mar 22, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7196184?
Alnylam Europe AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.
When does US 7196184 expire?
Our index shows an expiration date of Mar 22, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.